Dugel
Principal executive officer pay for Dugel, by year and company, from pay-versus-performance disclosure. Every figure links to its source on the company page.
OCULAR THERAPEUTIX, INC (OCUL) FY2024–FY2025
Lagged peersTSR -52% vs peer group 32% over FY2024–FY2025
Paid for declineCAP $9,645,226→$57,534,937 while $100 invested went $122.53→$58.65 (FY2024–FY2025)
| Fiscal year | SCT total | Comp actually paid |
|---|---|---|
| FY2024 | $18.6M | $9.6M |
| FY2025 | $35.9M | $57.5M |
The company's "$100 invested" index ran $122.53 at FY2024 → $58.65 by FY2025 — an annualized return of -52.1%.
Track record
1 measurable tenure in the pay-versus-performance disclosure window. Best annualized TSR: -52.1%/yr at OCUL ( FY2024–FY2025). See the CEO track-record ranking for context.